Recent advances in the study, prevention, and treatment of infectious diseases

Journal of the Formosan Medical Association

Volumn 99, Issue 2, 2000, Pages 92-99

  Huang, Li Min ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acquired immunodeficiency syndrome; Combinatorial chemistry; Human immunodeficiency virus; Polymerase chain reaction; Structure based drug design; Vaccine

Indexed keywords

PROTEINASE INHIBITOR; SIALIDASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROGENESIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG STRUCTURE; GASTRODUODENAL ULCER; HELICOBACTER PYLORI; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; PATHOGENESIS; POLYMERASE CHAIN REACTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG DESIGN; HUMANS; VACCINATION;

EID: 0034112623     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Markham PD, Salahuddin SZ, Gallo RC: In vitro cultivation of normal and neoplastic human T lymphocytes. Clin Haematol 1984;13:423-46.
2. Sarin PS, Gallo RC: Human T-cell growth factor (TCGF). Crit Rev Immunol 1984;4:279-305.
3. Popovic M, Sarngadharan MG, Read E, et al: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984:224:497-500.
4. Salahuddin SZ, Ablashi DV, Markham PD, et al: Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986;234:596-601.
5. Frenkel N, Schirmer EC, Wyatt LS, et al: Isolation of a new herpesvirus from human CD4+ T cells. Proc Natl Acad Sci USA 1990;87:748-52.
6. Yamanishi K, Okuno T, Shiraki K, et al: Identification of human herpesvirus-6 as a causal agent for roseola infantum. Lancet 1988;i:1065-7.
7. Huang LM, Lee CY, Chen JY, et al: Primary human herpesvirus-6 infections in children: a prospective serologic study. J Infect Dis 1992;165:1163-4.
8. Huang LM, Kao YF, Lee CY, et al: Primary infections of human herpesvirus-7 and herpesvirus-6: a prospective, comparative study up to 6 years of age. Acta Paediatr 1997; 86:604-8.
9. Relman DA: The identification of uncultured microbial pathogens. J Infect Dis 1993;168:1-8.
10. Relman DA, Loutit JS, Schmidt TM, et al: The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens. N Engl J Med 1990;323: 1573-80.
11. Relman DA, Schmidt TM, MacDermott RP, et al: Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992;327:293-301.
12. Chang Y, Cesarman E, Pessin MS, et al: Human herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
13. Levy JA. Three new human herpesvirus (HHV6, 7, 8). Lancet 1997;349:558-62.
14. Simons JN, Pilot-Matias TJ, Leary TP, et al: Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995;92:3401-5.
15. Simons JN, Leary TP, Dawson GJ, et al: Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995;1:564-9.
16. Linnen J, Wages J Jr, Zhang-Keck ZY, et al: Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
17. Wang JT, Tsai FC, Lee CZ, et al: A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different clinical presentation compared with hepatitis C virus. Blood 1996;88:1881-6.
18. Kao JH, Chen DS: GB virus-C/hepatitis G virus infection in Taiwan: a virus that fails to cause a disease? J Biomed Sci 1999;6:220-5.
19. Huang LM, Pfeiffer BD, Cho CT: Human herpesvirus 6 infection. Acta Paediatr Sin 1997;38:1-7.
20. Sonnenberg A: Factors which influence the incidence and course of peptic ulcer. Scand J Gastroenterol 1988;155 (suppl):119-40.
21. Kuipers EJ, Blaser MJ: Helicobacter pylori and gastroduodenal disorders. In: Scheld WM, Armstrong D, Hughes JM, eds. Emerging Infections 1, Washington, DC: ASM Press, 1998;191-206.
22. Warren JR, Marshall BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; i:1273-5.
23. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
24. Sutton GC, Morrissey RA, Tobin JR Jr, et al: Pericardial and myocardial disease associated with serological evidence of infection by agents of the psittacosis-lymphogranuloma venereum group (Chlamydiaceae). Circulation 1967;36:830-8.
25. Dunne M: The association of Chlamydia pneumoniae and atherogenesis. In: Scheld WM, Craig WA, Hughes JM, eds. Emerging Infections 2, Washington, DC: ASM Press, 1998:105-23.
26. Gupta S, Leatham EW, Carrington D, et al: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
27. Gurfinkel E, Bozovich G, Daroca A, et al: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350:404-7.
28. Cutts FT, Olive JM: Vaccination programs in developing countries. In: Plotkin SA, Orenstein WA, eds. Vaccine. 3rd ed. Philadelphia: WB Saunders, 1999:1047-73.
29. Wright PF, Kim-Farley RJ, de Quadros CA. et al: Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 1991;325:1774-9.
30. Plotkin SL, Plotkin SA: A short history of vaccination. In: Plotkin SA, Orenstein WA, eds. Vaccine, 3rd ed. Philadelphia: WB Saunders, 1999:1-12.
31. CDC: Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:577-81.
32. Decker MD, Edwards KM: Combination vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccine, 3rd ed. Philadelphia: WB Saunders, 1999:508-30.
33. Chiu HH, Huang LM, Lee PI, et al: Diphtheria, tetanus, and whole cell pertussis vaccine combined with hepatitis B vaccines: a comparison of two doses (10 μg and 5 μg). Pediatr Infect Dis J 1998;17:206-11.
34. Lee CY, Thipphawong J, Huang LM, et al: An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type β-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 1999;103:25-30.
35. Kilbourne ED, Arden NH: Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccine, 3rd ed. Philadelphia: WB Saunders, 1999:531-51.
36. Valenzuela P, Medina A, Rutter WJ, et al: Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982;298:347-50.
37. Zinkernagel RM, Bachmann MF, Kundig TM, et al: On immunological memory. Ann Rev Immunol 1996;14: 333-67.
38. Montgomery DL, Ulmer JB, Donnelly JJ, et al: DNA vaccines. Pharmacol Ther 1997;74:195-205.
39. Wolff JA, Malone RW, Williams P, et al: Direct gene transfer into mouse muscle in vivo. Science 1990;247: 1465-8.
40. Ulmer JB, Donnelly JJ, Parker SE, et al: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
41. Anonymous: Adult immunization. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1984;33(suppl 1):1S-68S.
42. Reid KC, Grizzard TA, Poland GA: Adult immunizations: recommendations for practice. Mayo Clin Proc 1999;74: 377-84.
43. Oya A: Epidemiology of Japanese encephalitis, Rinsho to Biseibutsu. Clin Diagn Microbiol 1989;16:5-9.
44. Cheng KY, Tseng TC: Seroepidemiological investigation on Japanese encephalitis in Taiwan, Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih 1993;26:25-37.
45. Aoyama T, Takeuchi Y, Goto A, et al: Pertussis in adults. Am J Dis Child 1992;146:163-6.
46. Mink CA, Cherry JD, Christenson P, et al: A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992;14:464-71.
47. Long SS, Welkon CJ, Clark JL: Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990;161:480-6.
48. Cobbold S, Waldmann H: Infectious tolerance. Curr Opin Immunol 1998;10:518-24.
49. Rouse BT, Norley S, Martin S: Antiviral cytotoxic T lymphocyte induction and vaccination. Rev Infect Dis 1988;10:16-33.
50. Sher A, Coffman RL: Regulation of immunity to parasites by T cells and T cell-derived cytokines. Ann Rev Immunol 1992;10:385-409.
51. Raychaudhuri S, Rock KL: Fully mobilizing host defense: building better vaccines. Nat Biotech 1998;16:1025-31.
52. Allison AC: Immunological adjuvants and their modes of action. Arch Immunol Ther Exp(Warsz) 1997;45:141-7.
53. Vitiello A, Ishioka G, Grey HM, et al: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans, J Clin Invest 1995;95:341-9.
54. Benson EM, Clarkson J, Law M, et al: Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses 1999;15: 105-13.
55. Beasley RP, Trepo C, Stevens CE, et al: The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-8.
56. Beasley RP, Hwang LY, Lin CC, et al: Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982;146:198-204.
57. Ho DD: Viral counts count in HIV infection. Science 1996; 272:1124-5.
58. Connor EM, Sperling RS, Gelber R, et al: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
59. Chang CN, Skalski V, Zhou JH, et al: Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as antihepatitis B virus agents. J Biol Chem 1992;267:22414-20.
60. Furman PA, Davis M, Liotta DC, et al: The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-y1]cytosine. Antimicrob Agents Chemother 1992;36:2686-92.
61. Lai CL, Ching CK, Tung AK, et al: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-4.
62. Nevens F, Main J, Honkoop P, et al: Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
63. Murphy M, Armstrong D, Sepkowitz KA, et al: Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997;11:261-2.
64. Burdick AE, Carmichael C, Rady PL, et al: Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol 1997;37:648-9.
65. Dore GJ, Li Y, Grulich AE, et al: Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS 1996;10:1401-6.
66. Joffe MM, Hoover DR, Jacobson LP, et al: Effect of treatment with zidovudine on subsequent incidence of Kaposi's sarcoma. Clin Infect Dis 1997;25:1125-33.
67. Amzel LM: Structure-based drug design. Curr Opin Biotechnol 1998;9:366-9.
68. Lam PY, Jadhav PK, Eyermann CJ, et al: Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994;263:380-4.
69. Korant BD, Rizzo CJ: The HIV protease and therapies for AIDS. Adv Exp Med Biol 1997;421:279-84.
70. Mouton Y, Alfandari S, Valette M, et al: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation Nationale des Centres de Lutte contre le SIDA. AIDS 1997;11:F101-5.
71. Patriarca PA: New options for prevention and control of influenza. JAMA 1999;282:75-7.
72. Monto AS, Robinson DP, Herlocher ML, et al: Zanamivir in the prevention of influenza among healthy adults. JAMA 1999;282:31-5.
73. Salemme FR, Spurlino J, Bone R: Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Structure 1997;5:319-24.
74. Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993;21 (suppl):S423-35.
75. McGuire W, Hill AV, Allsopp CE, et al: Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-10.
76. McGuire W, Knight JC, Hill AV, et al: Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 1999;179:287-90.
77. Cairns JS, D'Souza MP: Chemokines and HIV-1 second receptors: the therapeutic connection. Nat Med 1998;4: 563-8.
78. Liu R, Paxton WA, Choe S, et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86: 367-77.
79. Huang Y, Paxton WA, Wolinsky SM, et al: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3.